Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polylaminin for acute spinal cord injury
RBR-9dfvgpmCompleted
- Sponsor
- Secretaria Municipal de Saúde do Rio de Janeiro
- Start
- Jan 2016
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of CRIS100 in spinal cord injury (SCI), sponsored by Secretaria Municipal de Saúde do Rio de Janeiro. Started Jan 2016; status: completed.
02
Drugs
CRIS100
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on RBR-9dfvgpm.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9dfvgpm.